Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
Radionuclide therapy
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "Radionuclide therapy" in MCE Product Catalog:
1
Target:
1
Target:
Research Areas:
2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as 68Ga, 177Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine .
Cat. No.: HY-139564
CAS No.: 1908409-18-6
Research Areas:
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .
Cat. No.: HY-164574
CAS No.: 2565792-45-0
Research Areas:
BCN-DOTA is a cyclooctyne-linked DOTA chelator. BCN-DOTA integrates BCN and DOTA, enabling conjugation with azide-functionalized groups via the click chemistry properties of BCN, while binding to metal ions through the coordination capacity of DOTA. BCN-DOTA can serve as a radionuclide-drug conjugate (RDC) to target specific biomolecules, cells or tissues after radiolabeling with zirconium-89. BCN-DOTA is applicable to research related to PET imaging and targeted therapy .
Cat. No.: HY-173374
CAS No.: 3114056-16-2
Target:
Research Areas:
DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan (HY-147057). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with 111In and 225Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors .
Cat. No.: HY-P10239
CAS No.: 302794-43-0
Research Areas:
Cat. No.: HY-P10732
CAS No.: 909024-55-1
Research Areas:
DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
Cat. No.: HY-W873634
CAS No.: 1242003-07-1
Synonyms: TRAP-Pr
Research Areas:
TRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.
Cat. No.: HY-175744
CAS No.: 3077205-52-5
PSMA-MAL-5 is a PSMA ligand. PSMA-MAL-5 covalently binds to Cys466 of PSMA. PSMA-MAL-5 labeled with 177Lu and 225Ac has high radiostability and tumor uptake. PSMA-MAL-5 also effectively inhibits tumor growth. PSMA-MAL-5 can be used for SPECT/CT imaging and radionuclide therapy of prostate cancer .
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
Cat. No.: HY-W035399S
Cat. No.: HY-164653
CAS No.: 137076-50-7
Research Areas:
DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
Cat. No.: HY-164590
CAS No.: 2256055-98-6
Research Areas:
BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
Cat. No.: HY-P10730
CAS No.: 213187-44-1
Research Areas:
DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
Cat. No.: HY-164594
Research Areas:
TA-DOTA-GA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
Cat. No.: HY-W087187G
CAS No.: 1375475-53-8
Cat. No.: HY-164589
CAS No.: 1397275-76-1
Research Areas:
NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
